Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that intralesional methotrexate and triamcinolone acetonide have similar efficacy for localized alopecia areata in adults, but differ in safety profiles, with methotrexate associated with hyperpigmentation and triamcinolone with atrophy.

This study analyzed online discussions and search behavior in Gulf countries, uncovering significant engagement and identifying gaps in awareness and understanding of alopecia areata among patients and healthcare professionals, suggesting a need for targeted educational initiatives to enhance support and reduce stigma.

In this study, the researchers developed a quantum algorithm, QuantAnts machines, which identified complexes of CD9, CD34, and CD74 as potential targets for certain cancers involving the RAS pathway.

This study found that tofacitinib may inhibit CD8+ T cell infiltration in alopecia areata by affecting the linoleic acid metabolism-Mg2+ pathway in a sodium sulfide-induced mouse model, highlighting new insights for clinical diagnosis and treatment strategies.

This study highlights the role of immune dysregulation, microRNA modulation, and SIRT1 pathways in alopecia areata, suggesting antisense oligonucleotides targeting miR-485-3p as a promising therapeutic strategy for promoting hair regrowth and reducing inflammation in murine models.

This study examined FAERS data and found an increasing trend in alopecia areata cases, with monoclonal antibodies most frequently linked to the condition.

This report highlights a case of a 35-year-old man developing alopecia universalis following alemtuzumab treatment for multiple sclerosis, suggesting potential links between this medication and drug-induced alopecia areata, though the genetic overlap of the conditions may also play a role.

In this study, the authors discuss that while traditional alopecia areata treatments like corticosteroids offer limited efficacy and pose long-term adverse effects, new treatments using janus kinase inhibitors show potential for changing treatment protocols, pending a better understanding of associated adverse drug events.

In this study, analysis of FDA data revealed a substantial risk of dermatologic adverse events with aromatase inhibitors, especially anastrozole and exemestane, highlighting the importance of dermatologic monitoring during such therapies.

This study suggests that combining microneedling with ALA-photodynamic therapy may be a promising treatment option for moderate to severe alopecia areata, achieving significant hair regrowth in some patients.

This abstract provides supplementary materials and directs queries to the corresponding author but presents no new research findings.

This study found that patients with alopecia areata have significantly higher medication adherence than those with atopic dermatitis, potentially due to the stability and controllability of alopecia areata symptoms.

This study identified Saponin Re and Emodin as top candidates for treating androgenetic alopecia, suggesting future research in dermal papilla cell cultures and scalp organoids despite safety concerns.

This study found that MDA-modified DNA may contribute to immune responses in alopecia areata patients by creating neo-epitopes, providing new insights into the condition's immunological mechanisms.

In this study, patients with alopecia areata indicated a preference for shared decision-making (SDM) with their dermatologists, and those who engaged in SDM reported less decisional regret about their treatment choices.

ACTH promotes hair growth in mink, but α-MSH does not.

This study surveyed Irish dermatologists and found that while JAK inhibitors show promising efficacy for alopecia areata, there is significant variation in practice due to the lack of specific guidelines and long-term safety data for these treatments.

This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.

This study identified a four-gene loop as a non-invasive biomarker that selectively activates in alopecia areata, providing a precise target for JAK inhibitor treatments.

Alopecia areata is complex, with genetic and immune factors, and animal models are key for future treatment research.

This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

This study found that cyclin-dependent kinase 4/6 inhibitors used for metastatic breast cancer caused alopecia resembling androgenetic alopecia, negatively impacting patients' quality of life, but topical minoxidil showed potential for improvement.

In this study, in silico analysis identified Saponin Re and Emodin as promising candidates for topical treatment of androgenetic alopecia, with Biochanin A having the most favorable safety profile among the tested compounds.

Machine learning can use blood tests to help predict moderate-to-severe alopecia areata.

This article reviews multiple treatments for alopecia areata, highlighting their variable efficacy and safety without any being curative; it reports no new clinical findings.

A new microneedle patch effectively and safely treats alopecia areata.

A certain gene variation can affect protein production and is linked to male pattern baldness.

In this study, researchers developed an AI-powered platform called VitaDetect, which screens for vitamin deficiencies using image analysis of nails, tongue, and skin, aiming to provide an accessible and early-stage detection tool in resource-limited settings.

This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.